Top Ten 2024: Drug Pricing—340B Developments to Watch
Episode 26 min 16s

Top Ten 2024: Drug Pricing—340B Developments to Watch

Based on AHLA’s annual Health Law Connections article, this special series brings together thought leaders from across the health law field to discuss the top ten issues of 2024. In the tenth episode, Sarah Bowman, Principal, PYA, speaks with Jolee H. Bollinger, Deputy General Counsel, Sharp HealthCare, and Andrew D. Ruskin, Partner, K&L Gates LLP, about potential 340B activity in 2024 as drug manufacturers continue to tighten access to 340B pricing. They discuss the impact of the Genesis...

You May Also Like

Community discussion